FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5152
Abstract: Background: The FLAG-IDA (fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor, and idarubicin) regimen is rarely used as frontline induction therapy for pediatric patients with de novo acute myeloid leukemia (AML). Therefore, this study aimed to assess… read more here.
Keywords: frontline induction; flag ida; pediatric patients; kmt2a rearranged ... See more keywords
Treatment outcome and prognostic factor in fit elderly patients with multiple myeloma received frontline induction of bortezomib based regimen (PAD or VCD)
Sign Up to like & getrecommendations! Published in 2017 at "Translational cancer research"
DOI: 10.21037/13818
Abstract: Background: Few clinical trials have head to head compared bortezomib, doxorubicin and dexamethasone (PAD) and bortezomib, cyclophosphamide and dexamethasone (VCD) regimen in multiple myeloma (MM), especially for the elderly patients. Methods: In this study, we… read more here.
Keywords: pad vcd; frontline induction; multiple myeloma; bortezomib ... See more keywords